Roselle Abraham, MD

Associate Professor

CLINICAL INTERESTS: Dr. Roselle Abraham is a cardiologist with expertise in the treatment of patients with hypertrophic cardiomyopathy.

RESEARCH INTERESTS: Dr. Roselle Abraham is a physician scientist with a background in electrophysiology, imaging and stem cell research. She is using multi-modality imaging for risk stratification of atrial and ventricular arrhythmias. The overall goal of her research program is to use a combination of multi-modality clinical imaging and studies in model systems to tailor therapies for patients with hypertrophic cardiomyopathy.
Publications
  1. A variable resolution approach for improved acquisition of hyperpolarized 13 C metabolic MRI.
  2. Correction to: Comparison of two software systems for quantification of myocardial blood flow in patients with hypertrophic cardiomyopathy.
  3. Identifying Ventricular Arrhythmias and Their Predictors by Applying Machine Learning Methods to Electronic Health Records in Patients With Hypertrophic Cardiomyopathy (HCM-VAr-Risk Model).
  4. Allele-specific differences in transcriptome, miRNome, and mitochondrial function in two hypertrophic cardiomyopathy mouse models.
  5. Clinical Outcomes in Patients With Nonobstructive, Labile, and Obstructive Hypertrophic Cardiomyopathy.
  6. Rest and Stress Longitudinal Systolic Left Ventricular Mechanics in Hypertrophic Cardiomyopathy: Implications for Prognostication.
  7. Stress Myocardial Blood Flow Heterogeneity Is a Positron Emission Tomography Biomarker of Ventricular Arrhythmias in Patients With Hypertrophic Cardiomyopathy.
  8. Comparison of two software systems for quantification of myocardial blood flow in patients with hypertrophic cardiomyopathy.
  9. E/e' ratio and outcome prediction in hypertrophic cardiomyopathy: the influence of outflow tract obstruction.
  10. Impact of peak provoked left ventricular outflow tract gradients on clinical outcomes in hypertrophic cardiomyopathy.
  11. Plasma homocysteine levels associated with a corrected QT interval.
  12. Structural and Functional Correlates of Myocardial T1 Mapping in 321 Patients With Hypertrophic Cardiomyopathy.
  13. Role of Global Longitudinal Strain in Predicting Outcomes in Hypertrophic Cardiomyopathy.
  14. Exercise-QTc is associated with diffuse interstitial fibrosis reflected by lower approximated T1 relaxation time in hypertrophic cardiomyopathy patients.
  15. Diffuse interstitial fibrosis assessed by cardiac magnetic resonance is associated with dispersion of ventricular repolarization in patients with hypertrophic cardiomyopathy.
  16. Safety profile and utility of treadmill exercise in patients with high-gradient hypertrophic cardiomyopathy.
  17. Effect of Diffuse Subendocardial Hypoperfusion on Left Ventricular Cavity Size by 13N-Ammonia Perfusion PET in Patients With Hypertrophic Cardiomyopathy.
  18. Metabolism rather than obesity is associated with ischemic stroke: a cross-sectional study in rural Northeastern China.
  19. The Relation of Moderate Alcohol Consumption to Hyperuricemia in a Rural General Population.
  20. Common miR-590 Variant rs6971711 Present Only in African Americans Reduces miR-590 Biogenesis.
  21. Left ventricular wall thickness in patients with hypertrophic cardiomyopathy: a comparison between cardiac magnetic resonance imaging and echocardiography.
  22. Echocardiographic Characterization of a Murine Model of Hypertrophic Obstructive Cardiomyopathy Induced by Cardiac-specific Overexpression of Epidermal Growth Factor Receptor 2.
  23. Shape analysis of hypertrophic and hypertensive heart disease using MRI-based 3D surface models of left ventricular geometry.
  24. Comparison of Outcomes in Patients With Nonobstructive, Labile-Obstructive, and Chronically Obstructive Hypertrophic Cardiomyopathy.
  25. Late gadolinium enhancement confined to the right ventricular insertion points in hypertrophic cardiomyopathy: an intermediate stage phenotype?
  26. Apparent left ventricular cavity dilatation during PET/CT in hypertrophic cardiomyopathy: Clinical predictors and potential mechanisms.
  27. Utilizing ECG-Based Heartbeat Classification for Hypertrophic Cardiomyopathy Identification.
  28. Exercise heart rates in patients with hypertrophic cardiomyopathy.
  29. Identifying Hypertrophic Cardiomyopathy Patients by Classifying Individual Heartbeats from 12-lead ECG Signals.
  30. Age-related changes in familial hypertrophic cardiomyopathy phenotype in transgenic mice and humans.
  31. Hypertrophic cardiomyopathy: a heart in need of an energy bar?
  32. Comparison of clinical presentation, left ventricular morphology, hemodynamics, and exercise tolerance in obese versus nonobese patients with hypertrophic cardiomyopathy.
  33. Electromechanical relationship in hypertrophic cardiomyopathy.
  34. Creatine kinase adenosine triphosphate and phosphocreatine energy supply in a single kindred of patients with hypertrophic cardiomyopathy.
  35. Relationship of delayed enhancement by magnetic resonance to myocardial perfusion by positron emission tomography in hypertrophic cardiomyopathy.
  36. In hypertrophic cardiomyopathy reduction of relative resting myocardial blood flow is related to late enhancement, T2-signal and LV wall thickness.
  37. Comparison and effectiveness of regadenoson versus dipyridamole on stress electrocardiographic changes during positron emission tomography evaluation of patients with hypertrophic cardiomyopathy.
  38. Cardiac MRI evaluation of hypertrophic cardiomyopathy: left ventricular outflow tract/aortic valve diameter ratio predicts severity of LVOT obstruction.
  39. PET/CT assessment of symptomatic individuals with obstructive and nonobstructive hypertrophic cardiomyopathy.
  40. Constitutive HIF-1a expression blunts the beneficial effects of cardiosphere-derived cell therapy in the heart by altering paracrine factor balance.
  41. Anatomy of the tendinous cords of the interventricular septum of the human heart.
  42. Stem cell: "KANT" you see it?
  43. Angiotensin-converting enzyme genotype modulates pulmonary function and exercise capacity in treated patients with congestive stable heart failure.